These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29176092)

  • 1. Regional Variations in the Interpretation of the End-Stage Renal Disease Thirty-Month Coordination Period: Potential Implications for Patient Care.
    Harford R; Clark MJ; Yan G; Flaque J; Colon J; Torre F; Rodriguez Y; Norris KC
    J Health Care Poor Underserved; 2017; 28(4):1245-1253. PubMed ID: 29176092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Adjustment and the Assessment of Disparities in Dialysis Mortality Outcomes.
    Kalbfleisch J; Wolfe R; Bell S; Sun R; Messana J; Shearon T; Ashby V; Padilla R; Zhang M; Turenne M; Pearson J; Dahlerus C; Li Y
    J Am Soc Nephrol; 2015 Nov; 26(11):2641-5. PubMed ID: 25882829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls.
    Roach JL; Turenne MN; Hirth RA; Wheeler JR; Sleeman KS; Messana JM
    Am J Kidney Dis; 2010 Nov; 56(5):928-36. PubMed ID: 20888100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race, Ethnicity, and End-of-Life Care in Dialysis Patients in the United States.
    Foley RN; Sexton DJ; Drawz P; Ishani A; Reule S
    J Am Soc Nephrol; 2018 Sep; 29(9):2387-2399. PubMed ID: 30093455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and Ethnic Variations in Mortality Rates for Patients Undergoing Maintenance Dialysis Treated in US Territories Compared with the US 50 States.
    Yan G; Shen JI; Harford R; Yu W; Nee R; Clark MJ; Flaque J; Colon J; Torre F; Rodriguez Y; Georges J; Agodoa L; Norris KC
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):101-108. PubMed ID: 31857376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare program; end-stage renal disease prospective payment system. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Dialysis and its Financing.
    Borelli M; Paul DP; Skiba M
    Hosp Top; 2016; 94(2):33-8. PubMed ID: 27315562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
    Ishani A; Guo H; Arneson TJ; Gilbertson DT; Mau LW; Li S; Dunning S; Collins AJ
    J Am Soc Nephrol; 2009 Jul; 20(7):1607-13. PubMed ID: 19389846
    [No Abstract]   [Full Text] [Related]  

  • 10. Health Policy and Kidney Care in the United States: Core Curriculum 2020.
    Mendu ML; Weiner DE
    Am J Kidney Dis; 2020 Nov; 76(5):720-730. PubMed ID: 32771281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
    Iglehart JK
    N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States.
    Devlin A; Waikar SS; Solomon DH; Lu B; Shaykevich T; Alarcón GS; Winkelmayer WC; Costenbader KH
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1642-53. PubMed ID: 22058067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Futuristic plans for ESRD--a new bundled payment system.
    Michael M
    Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649
    [No Abstract]   [Full Text] [Related]  

  • 15. For-profit versus not-for-profit dialysis care for children with end stage renal disease.
    Furth SL; Hwang W; Neu AM; Fivush BA; Powe NR
    Pediatrics; 1999 Sep; 104(3 Pt 1):519-24. PubMed ID: 10469779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Evidence behind Policy Mandates in US Dialysis Care.
    Erickson KF; Winkelmayer WC
    J Am Soc Nephrol; 2018 Dec; 29(12):2777-2779. PubMed ID: 30389727
    [No Abstract]   [Full Text] [Related]  

  • 17. The organization and financing of kidney dialysis and transplant care in the United States of America.
    Hirth RA
    Int J Health Care Finance Econ; 2007 Dec; 7(4):301-18. PubMed ID: 17602296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home Dialysis Utilization Among Racial and Ethnic Minorities in the United States at the National, Regional, and State Level.
    Wallace EL; Lea J; Chaudhary NS; Griffin R; Hammelman E; Cohen J; Sloand JA
    Perit Dial Int; 2017 1-2; 37(1):21-29. PubMed ID: 27680759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bundling and its potential impact on dialysis service providers.
    Sullivan J
    Nephrol News Issues; 2008 Oct; 22(11):12, 14, 16-7. PubMed ID: 19009855
    [No Abstract]   [Full Text] [Related]  

  • 20. What can we learn from the U.S. expanded end-stage renal disease bundle?
    Chambers JD; Weiner DE; Bliss SK; Neumann PJ
    Health Policy; 2013 May; 110(2-3):164-71. PubMed ID: 23419419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.